Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway.
Zheng ZG, Zhu ST, Cheng HM, Zhang X, Cheng G, Thu PM, Wang SP, Li HJ, Ding M, Qiang L, Chen XW, Zhong Q, Li P, Xu X.
Autophagy. 2021 Jul;17(7):1592-1613. doi: 10.1080/15548627.2020.1757955. Epub 2020 May 20.
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).
Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, An P, Li H, Yan S, Ma Q, Deng H, Qian L, Zhou Y; CREDIT-2 investigators.
BMC Med. 2023 Feb 28;21(1):77. doi: 10.1186/s12916-023-02797-8.
PMID:36855099
[Effect of Herbal-cake-separated Moxibustion on Blood Lipid Levels and Expression of Hepatic PPARgamma and SR-B 1 Proteins and Genes in Hyperlipidemia Atherosclerosis Rabbits].
Zou YF, Ma MZ, Zhao Z, Tan J, Yang JJ, Shi J, Liu M, Liu ML, Chang XR.
Zhen Ci Yan Jiu. 2018 Feb 25;43(2):86-91. doi: 10.13702/j.1000-0607.170729.
PMID:29516695
Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta-Analysis of Randomised Controlled Trials.
Basit J, Ahmed M, Singh P, Ahsan A, Zulfiqar E, Iqbal J, Fatima M, Upreti P, Hamza M, Alraies MC.